The Centers for Medicare & Medicaid Services issued its final payment decision regarding the Cologuard stool DNA colorectal cancer screening test, and will reimburse it at $502 per test.
FDA granted clearance for IQQA-BodyImaging, developed by EDDA Technology, as the latest addition to the IQQA platform and product suite for imaging-guided cancer treatment.
The Broad Institute, Harvard University, the Massachusetts Institute of Technology and Editas Medicine entered into a worldwide license agreement to grant Editas access to intellectual property related to the the CRISPR-Cas9 system genome editing technology.
FDA approved Cyramza (ramucirumab) in combination with paclitaxel as a treatment for advanced or metastatic stomach or gastroesophageal junction adenocarcinoma whose cancer has progressed on or after prior fluoropyrimidine- or platinum-containing chemotherapy.
VELOS recently activated its Investigational Drug System at MD Anderson Cancer Center.
UNIVERSITY HOSPITALS Case Medical Center and UH Seidman Cancer Center selected GO Clinical Workbench developed by GenomOncology for workflow management of next generation sequencing data.
QIAGEN N.V. and Astellas Pharma Inc. will collaborate to develop and commercialize companion diagnostics paired with Astellas drugs for use in cancer and other diseases.
FDA approved the expanded use of Lymphoseek (technetium Tc 99m tilmanocept) injection for lymphatic mapping in solid tumors, and adding sentinel lymph node detection for breast cancer and melanoma to the approved indications.
FDA approved bortezomib (Velcade) injection for previously untreated patients with mantle cell lymphoma.
The European Commission granted marketing approval for Imbruvica (ibrutinib) throughout the European Union, for relapsed or refractory mantle cell lymphoma, or chronic lymphocytic leukemia patients who have received at least one prior therapy, or in first line CLL patients in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemotherapy.
